发布求助
文献互助 智能选刊 最新文献

Clinical pharmacology and therapy最新文献

筛选
英文 中文
Prognostic value of echocardiographic parameters in patients with pulmonary embolism 超声心动图参数对肺栓塞患者的预后价值
Clinical pharmacology and therapy Pub Date : 2021-09-05 DOI: 10.32756/0869-5490-2021-3-52-56
J. E. Netylko, M. Teterina, A. Pisaryuk, L. Goreva, O. Lukina, A. Safarova, I. Merai, Z. Kobalava
{"title":"Prognostic value of echocardiographic parameters in patients with pulmonary embolism","authors":"J. E. Netylko, M. Teterina, A. Pisaryuk, L. Goreva, O. Lukina, A. Safarova, I. Merai, Z. Kobalava","doi":"10.32756/0869-5490-2021-3-52-56","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-52-56","url":null,"abstract":"To assess the value of echocardiographic parameters in predicting hospital death in patients with pulmonary embolism (PE).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81430703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pathogenesis and treatment of spasticity 痉挛的发病机制和治疗
Clinical pharmacology and therapy Pub Date : 2021-09-05 DOI: 10.32756/0869-5490-2021-3-18-24
E. Katunina
{"title":"Pathogenesis and treatment of spasticity","authors":"E. Katunina","doi":"10.32756/0869-5490-2021-3-18-24","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-18-24","url":null,"abstract":"In a review article, the author discusses the mechanisms of spasticity after stroke, its clinical manifestations and approaches to treatment including physical therapy, surgery and the use of central (tolperisone, baclophen and tizanidine) and peripheral (botulinum toxin A) acting muscle relaxants.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77731563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparative efficacy of the original and biosimilar eculizumab in the treatment of obstetric atypical hemolytic-uremic syndrome eculizumab原药与生物仿制药治疗产科非典型溶血性尿毒症综合征的疗效比较
Clinical pharmacology and therapy Pub Date : 2021-09-05 DOI: 10.32756/0869-5490-2021-3-25-30
Y. Korotchaeva, N. Kozlovskaya, E. Shifman
{"title":"Comparative efficacy of the original and biosimilar eculizumab in the treatment of obstetric atypical hemolytic-uremic syndrome","authors":"Y. Korotchaeva, N. Kozlovskaya, E. Shifman","doi":"10.32756/0869-5490-2021-3-25-30","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-25-30","url":null,"abstract":"Obstetric atypical hemolytic-uremic syndrome (aHUS) is an emergency with an unfavorable prognosis. The implementation of the complement-blocking drug Eculizumab into clinical practice significantly improved prognosis of patients with obstetric aHUS. In 2019, the first biosimilar of Eculizumab was developed in Russia by GENERIUM.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79196190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Levilimab in patients with COVID-19 in real-life practice 来利单抗在COVID-19患者中的应用
Clinical pharmacology and therapy Pub Date : 2021-09-05 DOI: 10.32756/0869-5490-2021-3-31-37
E.V. Tavlueva, I. G. Ivanov, K. Lytkina, P.A. Plesovskiy, T. V. Bezuglaya, S. Fridman, T. Meleshkevich, V. V. Strizheletskiy, G. Melkonyan, G.Yu. Melik-Ogandzhanyan, M. Uyanaeva, E. A. Bezuglaya, D. N. Khobotnikov, P. Pukhtinskaia, V. Mladov
{"title":"Levilimab in patients with COVID-19 in real-life practice","authors":"E.V. Tavlueva, I. G. Ivanov, K. Lytkina, P.A. Plesovskiy, T. V. Bezuglaya, S. Fridman, T. Meleshkevich, V. V. Strizheletskiy, G. Melkonyan, G.Yu. Melik-Ogandzhanyan, M. Uyanaeva, E. A. Bezuglaya, D. N. Khobotnikov, P. Pukhtinskaia, V. Mladov","doi":"10.32756/0869-5490-2021-3-31-37","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-31-37","url":null,"abstract":"To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86922335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Direct oral anticoagulants for prevention of recurrent stroke in patients with atrial fibrillation 直接口服抗凝剂预防房颤患者卒中复发
Clinical pharmacology and therapy Pub Date : 2021-09-05 DOI: 10.32756/0869-5490-2021-3-57-66
S. Moiseev
{"title":"Direct oral anticoagulants for prevention of recurrent stroke in patients with atrial fibrillation","authors":"S. Moiseev","doi":"10.32756/0869-5490-2021-3-57-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-57-66","url":null,"abstract":"A history of stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (AF) is associated with a two-fold increase in risk of recurrent stroke. Without anticoagulation the annual incidence of recurrent stroke in these patients ranges from 6% to 9% and significantly exceeds this in patients with other risk factors for thromboembolic events. Meta-analysis of randomised clinical trials (RCT) suggested that direct oral anticoagulants (DOAC) are more effective and safe than warfarin and should be preferred treatment in patients with AF and previous stroke/TIA. Several RCTs are investigating optimal timing of (re)initiation of anticoagulation after acute ischemic stroke. Current guidelines suggest that in most patients treatment with anticoagulants may be initiated within 4-14 days after the onset of acute ischemic stroke depending on its severity and infarct size. Aspirin is recommended until oral anticoagulant therapy is initiated.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90354867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Rituximab in systemic sclerosis 利妥昔单抗治疗系统性硬化症
Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI: 10.32756/0869-5490-2021-2-31-35
T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov
{"title":"Rituximab in systemic sclerosis","authors":"T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov","doi":"10.32756/0869-5490-2021-2-31-35","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-31-35","url":null,"abstract":"To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79709295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olokizumab for treatment of rheumatoid arthritis Olokizumab用于治疗类风湿性关节炎
Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI: 10.32756/0869-5490-2021-2-67-74
S. Moiseev, P. Novikov, N. Chebotareva, S. Gulyaev, N. Bulanov, T. Schevtsova, E. Shchegoleva
{"title":"Olokizumab for treatment of rheumatoid arthritis","authors":"S. Moiseev, P. Novikov, N. Chebotareva, S. Gulyaev, N. Bulanov, T. Schevtsova, E. Shchegoleva","doi":"10.32756/0869-5490-2021-2-67-74","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-67-74","url":null,"abstract":"Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents. The efficacy and favorable safety profile of olokizumab in combination with methotrexate in rheumatoid arthritis patients who had previously failed methotrexate or tumour necrosis factor inhibitors were established in the several international 3 phase clinical trials (CREDO). The authors present two cases of successful olokizumab administration and discuss the indications for its use in patients with rheumatoid arthritis to achieve clinical improvement and to prevent progression of AA-amyloidosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"8 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90720858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tafamidis in transthyretin amyloid cardiomyopathy Tafamidis在转甲状腺素淀粉样心肌病中的作用
Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI: 10.32756/0869-5490-2021-2-44-50
S. Moiseev, V. Rameev
{"title":"Tafamidis in transthyretin amyloid cardiomyopathy","authors":"S. Moiseev, V. Rameev","doi":"10.32756/0869-5490-2021-2-44-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-44-50","url":null,"abstract":"Transthyretin is primarily synthesized in the liver and transports thyroxine and vitamin A in the body. The transthyretin when dissociated into monomers can misfold and ultimately form amyloid fibrils. There are two types of ATTR amyloidosis: hereditary (caused by mutations in the TTR gene) and wild-type (also referred to as senile systemic amyloidosis). Amyloid cardiomyopathy can develop in patients with both types of ATTR amyloidosis, has a later onset and is characterized by progressive heart failure leading to death within a few years after diagnosis. Tafamidis is an oral-administered small molecule that binds to transthyretin and inhibits transthyretin tetramer dissociation, the rate-limiting step in the amyloidosis. Long-term efficacy and safety of tafamidis were shown in patients with transthyretin familial amyloid polyneuropathy. The objective of the phase 3 international, multicenter, double-blind, placebo-controlled, randomized ATTR-ACT study was to evaluate the efficacy, safety, and tolerability of tafamidis (20 or 80 mg orally QD) in comparison with placebo in 441 patients with hereditary and nonhereditary transthyretin cardiomyopathy (median age 75 years, 90% of males). At month 30, treatment with tafamidis was associated with a lower risk of all-cause mortality (by 30%) and a lower rate of cardiovascular related hospitalizations (by 32%) than placebo and resulted in a lower rate of decline in distance for the 6-minute walk test and a lower rate of decline in KCCQ-OS score. The data from extension study supports tafamidis 80 mg as the optimal dose (bioequivalent to tafamidis free acid 61 mg).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73160004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Efficacy and safety of Xa factor antagonists in patients with nonvalvular atrial fibrillation Xa因子拮抗剂在非瓣膜性心房颤动患者中的疗效和安全性
Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI: 10.32756/0869-5490-2021-2-59-66
V.N. Drozdovа, E.K. Kochetkovaа
{"title":"Efficacy and safety of Xa factor antagonists in patients with nonvalvular atrial fibrillation","authors":"V.N. Drozdovа, E.K. Kochetkovaа","doi":"10.32756/0869-5490-2021-2-59-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-59-66","url":null,"abstract":"Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events and for prevention of stroke and systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics of patient, a need in prolonged or life-long treatment, concomitant diseases, the use of other drugs interacting with anticoagulants increase the risk of side effects of anticoagulation. We analyzed the current data on the efficacy and safety of Xa factor antagonists, as well as the features of their use in the event of adverse reactions, particularly bleedings. The possibilities of monitoring the efficacy and safety of treatment with these drugs were evaluated.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74004828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial Mediterranean fever: diagnostic issues and treatment options 家族性地中海热:诊断问题和治疗方案
Clinical pharmacology and therapy Pub Date : 2021-06-01 DOI: 10.32756/0869-5490-2021-2-36-43
V. Rameev, A. Simonyan, M. Bogdanova, L. Lysenko, S. Moiseev
{"title":"Familial Mediterranean fever: diagnostic issues and treatment options","authors":"V. Rameev, A. Simonyan, M. Bogdanova, L. Lysenko, S. Moiseev","doi":"10.32756/0869-5490-2021-2-36-43","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-36-43","url":null,"abstract":"To evaluate diagnostic and treatment issues in patients with familial Mediterranean fever (FMF) and risk factors for AA-amyloidosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75815768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信